Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Clin Transplant. 2012 Jul-Aug;26(4):615–621. doi: 10.1111/j.1399-0012.2011.01582.x

Table 2.

Diagnostic Yield Characteristics

Total (%)
Overall 45

  Diagnosis by PLB 24 (53)
  Diagnosis by secondary method 19 (42)
  Lost to follow-up 2 (4)

Diagnosed by Percutaneous Lung Biopsy 24

Benign etiology
  “Proven” fungal disease* 12 (26)
  Bacterial infection 1 (2)
  Atypical mycobacterial infection 1 (2)
  Other benign# 1 (2)
Malignant etiology
  Primary lung cancer 4 (9)
 Metastatic disease 3 (7)
  Post-transplant lymphoproliferative disease 1 (2)
  Unknown primary 1 (2)
PLB Diagnosis by Type of Biopsy
  FNAB 9 (38)**
  FNAB + CB 15 (71)**

Diagnosed by Secondary Method 19

Benign etiology
  All invasive fungal disease* 8 (18)
  “Proven” fungal disease 4 (9)
  “Probable” fungal disease 1 (2)
  “Possible” fungal disease 3 (7)
  Bacterial infection 4 (9)
  Atypical mycobacterial infection 1 (2)
  Other benign# 3 (7)
Malignant etiology
  Primary lung cancer 2 (4)
  Lymphoma 1 (2)
Secondary Diagnostic Method 19
  Surgical lung biopsy 7 (16)
  Bronchoscopy 3 (7)
  Clinical follow-up 6 (13)
  Microbiologic culture (blood) 2 (4)
  Fluid cytology (pleural) 1 (2)
*

: Based on EORTC/MSG criteria for diagnosis of fungal infections

: FNAB: Fine Needle Aspiration biopsy, CB: Core biopsy

**

: Denominator based on biopsy type: FNAB, n=24; FNAB + CB, n=21

#

: Other benign etiology includes: fibrous tissue, old granulomatous disease